DBV Technologies S.A. Business Summary

DBV Technologies S.A. is a clinical-stage biopharmaceutical company that generates revenue through the development and future commercialization of its proprietary Epicutaneous Immunotherapy (EPIT) platform. Its primary business segment is focused on the Viaskin technology, a non-invasive skin patch designed to desensitize patients to food allergens by delivering microgram amounts of antigens to the immune cells of the epidermis. As of February 2026, the company is transitioning toward a commercial-stage model following the successful Phase 3 VITESSE trial, with a planned Biologics License Application (BLA) submission for Viaskin Peanut in children aged 4–7 scheduled for the first half of 2026. Direct competitors include Stallergenes Greer (marketing Palforzia, though slated for discontinuation in mid-2026), Alladapt Immunotherapeutics, and Aravax. DBV positions itself as the market leader in patch-based immunotherapy, offering a safer, needle-free alternative to oral immunotherapy (OIT) by avoiding systemic bloodstream distribution and reducing the risk of anaphylaxis. The company was founded in 2002 by pediatric gastroenterologists Dr. Pierre-Henri Benhamou and Dr. Christophe Dupont, alongside Bertrand Dupont. The current leadership team is led by CEO Daniel Tassé, an industry veteran with previous chief executive roles at Alcresta Therapeutics and Ikaria. He is supported by Chief Medical Officer Dr. Pharis Mohideen, formerly of Shionogi and Novartis, and CFO Virginie Boucinha, who brought extensive financial expertise from Sanofi upon joining. In late 2025, the team was further strengthened by the appointment of Kevin Trapp as Chief Commercial Officer to oversee the anticipated U.S. launch. The company is governed by a board chaired by Michel de Rosen and includes notable directors such as Michael Goller and Maïlys Ferrère, representing significant backing from institutional investors like Sofinnova Partners and Bpifrance.